MilliExo®: the new frontier of autologous regenerative medicine

In recent years, autologous regenerative medicine has taken a decisive step towards innovation: MilliExo®, the patented protocol developed by Dual Trend Srl, now represents the perfect synthesis of research, biomedical engineering and clinical safety.
Based on an integrated system consisting of a sterile single-use kit and the exosome-activating device MilliExo Lab®, the protocol makes it possible to obtain, in just 45 minutes, an autologous concentrate of functional exosomes ready for outpatient use.

An integrated, simple and scientifically validated system

MilliExo® Kit: collects and filters adipose tissue through calibrated meshes of 50–80 µm, isolating viable MSCa cells and CD34⁺/CD146⁺ sub-populations.

MilliExo Lab®: activates exosomes under controlled hypoxic conditions and physiological temperature (~37 °C), reproducing the natural microenvironment.

Each phase is certified MDR 2017/745, ISO 13485:2015 and ISO 9001:2015, ensuring quality and full traceability.

Why it is unique

• Autologous by nature – no heterologous material; maximum biocompatibility.

• Fast and reproducible – can be performed in an outpatient setting, with no centrifuges or enzymes.

• Scientifically grounded – supported by more than 30 PubMed publications (Zuk 2002, Baer 2013, Zhu 2018, etc.).

MilliExo® opens a new era: safe, personalised, cell-free regenerative medicine.

A patented Made in Italy system that transforms science into clinical practice.